Skip to content

Sensitivity and specificity of 68 Ga-FAPI positron emission tomography/computed tomography for diagnosis of peritoneal metastasis in newly diagnosed locally advanced gastric cancer:A single center prospective cohort study

Sensitivity and specificity of 68 Ga-FAPI positron emission tomography/computed tomography for diagnosis of peritoneal metastasis in newly diagnosed locally advanced gastric cancer:A single center prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067591
Enrollment
Unknown
Registered
2023-01-12
Start date
2023-01-12
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Gold Standard:Staging Laparoscopy and Lavage Cytology

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients aged >=18 years;2.Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at study entry;3.Patients with histologically proven gastric and gastroesophageal junction (Siewert type III) carcinomas with newly diagnosed by gastroscopy;4.Surgically resectable, advanced gastric cancer (cT4a, N0-3, M0) on initial staging evaluation by contrast-enhanced CT of the chest, abdomen, and pelvis (according to the eighth edition of AJCC TNM staging system);5.Patients with adequate organ function, defined as no severe disfunction of the lungs, kidneys, heart, bone marrow, and clinical laboratory test value

Exclusion criteria

Exclusion criteria: 1.Siewert type I-II esophagogastric junction tumor and Patients with advanced gastric cancer of M1 in TNM staging on CT staging evaluation; 2.Patients with allergic constitution or with drug allergy; 3.Patients with active double primary malignancies; 4.Patients who are possibly pregnant, pregnant, unwilling to practice contraception during the study or breastfeeding; 5.Patients diagnosed with mental illness that they could have difficulty in participating in the trial; 6.Patients with history of previous abdominal inflammatory diseases (such as peritonitis, pancreatitis, cholecystitis, inflammatory bowel disease); 7.Patients with history of abdominal trauma; 8.Patients with history of cerebrovascular accident within past six months; 9.Patients with history of continuous systematic administration of corticosteroids within one month.

Design outcomes

Primary

MeasureTime frame
Proportion of changes in treatment strategy;

Secondary

MeasureTime frame
sensitivity;specificity;accuracy;positive predictive value;negative predictive value;SUVmax:maximum standardized uptake value;PCI;

Countries

China

Contacts

Public ContactGou Hongfeng

West China Hospital of Sichuan University

joan_gou1977@163.com18980602292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026